

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

Rec'd.PCT/APTO 21 JUN 2005

10/540139
PCT

To:

GERVASI, Gemma
NOTARBARTOLO & GERVASI S.p.A.
Corso di Porta Vittoria 9
I-20122 Milan
ITALIE

NOTARBARTOLO & GERVASI MILANO	
R E C E I V E D	
AP 21 MAR. 2005	
<i>[Signature]</i>	5U

**NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

(PCT Rule 71.1)

Date of mailing
(day/month/year)

17.03.2005

Applicant's or agent's file reference
2509PTWO

IMPORTANT NOTIFICATION

International application No.
PCT/EP 03/14740

International filing date (day/month/year)
22.12.2003

Priority date (day/month/year)
23.12.2002

Applicant
EURAND S.P.A. et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/B/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed inventions is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the international
preliminary examining authority:



European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized Officer

Hutterer, G

Tel. +49 89 2399-8066



PATENT COOPERATION TREATY
PCT
INTERNATIONAL PRELIMINARY EXAMINATION REPORT
(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 2509PTWO	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/EP 03/14740	International filing date (day/month/year) 22.12.2003	Priority date (day/month/year) 23.12.2002
International Patent Classification (IPC) or both national classification and IPC A61K9/14		
Applicant EURAND S.P.A. et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 5 sheets, including this cover sheet.
 - This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 3 sheets.

3. This report contains indications relating to the following items:
 - I Basis of the opinion
 - II Priority
 - III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
 - IV Lack of unity of invention
 - V Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
 - VI Certain documents cited
 - VII Certain defects in the international application
 - VIII Certain observations on the international application

Date of submission of the demand 20.07.2004	Date of completion of this report 17.03.2005
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized Officer Rauter, A Telephone No. +49 89 2399-8645



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP 03/14740

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, Pages

1-20 as originally filed

Claims, Numbers

1-20 filed with telefax on 15.02.2005

Drawings, Sheets

1/6-6/6 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- the language of publication of the international application (under Rule 48.3(b)).
- the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- contained in the international application in written form.
- filed together with the international application in computer readable form.
- furnished subsequently to this Authority in written form.
- furnished subsequently to this Authority in computer readable form.
- The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- the description, pages:
- the claims, Nos.:
- the drawings, sheets:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP 03/14740

5. This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims	1-10,15
	No: Claims	11-14,16-20
Inventive step (IS)	Yes: Claims	1-10
	No: Claims	11-20
Industrial applicability (IA)	Yes: Claims	1-20
	No: Claims	

2. Citations and explanations

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP 03/14740

SECTION V.

1. Reference is made to the following documents:

D1: EP-A-1 308 156 (WO-A-2 013 792)
D2: US-A-6 462 093
D3: US-A-5 972 381
D4: WO-A-9 800 113
D5: WPI/Derwent AN-1993-408839[34] & JP-A-5 306 225

2. The present application satisfies the criteria set forth in Article 33(1) PCT with respect to claims 1 - 10, because the subject-matter of the said claims is new in respect of prior art as defined in the regulations (Rule 64(1)-(3) PCT), involves an inventive step (Rule 65(1)(2) PCT) and is considered industrially applicable.

The subject-matter of claim 1 is considered new as the available prior art, eg D2 does not specifically disclose the teaching that in the claimed process in the irradiating step the microwave power is to be modulated as defined in step b).
D1, similarly does not indicate the power modulation and additionally does not mention presently specified carriers. The further citations comprise teachings which are no longer relevant for the claimed subject-matter.

The problem can be seen in the provision of further compositions having a high bioavailability of the contained drugs in amorphous form. Closest prior art represents D2, however, even if the remaining prior art is considered, the specific heat treatment step b) cannot be deduced in an obvious manner. The applicant pointed furthermore to test results which show that constant microwave power application results in completely decomposed products.

There is no doubt that the subject-matter claimed is industrially applicable.

3. The present application does not satisfy the criterion set forth in Article 33(1) PCT with respect to claims 11 - 20, because the subject-matter of the said claims is either not new in respect of prior art as defined in the regulations (Rule 64(1)-(3) PCT) or does not involve an inventive step (Rule 65(1)(2) PCT).

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP 03/14740

The claimed composite contains according to independent claim 11, essentially,

- cyclodextrins or maltodextrins as carrier,
- and
- a drug present in amorphous form $\geq 50\%$ with respect to the total drug present in the composite.

In claim 18, the composite is for use in therapy, and in claim 19 it is present in a composition.

Document D2 discloses in *eg* claims 7 or 8 compositions which comprise a composite comprising a drug, a cyclodextrin, and which drug is in the amorphous state (see also *eg* column 2, lines 54 - 64, etc). Concerning the specific embodiments of dependent claims 12 - 14, 16, 17 and 20, reference is made to claims 7, 8, 9, 10; column 3, line 19 of D2. Even if claim 15 is new, it is clearly obvious to the person skilled in the art.

There is no doubt that the subject-matter claimed is industrially applicable.

4. During the international preliminary examination procedure, the applicant has forwarded arguments concerning novelty and inventive step of present product claim 11, however they could not be considered as not reflected by the wording of the said independent claim.